Drugs / Vildagliptin
Vildagliptin
also known as
Galvus · LAF237 · - vildagliptine (Galvus) · Equa · Jalra · NVP-LAF 237 · Vilda · Vildagliptin (galvus) · +5 more
Other / unclassified targets DPP4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Galvus | — | 2007-09-25 | europa.eu ↗ |
Trials 147 · started per year
today
EU approved 2007
1
18
17
16
3
9
6
17
9
10
10
4
2
3
3
4
4
2
2
1
3
1
2
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials · 2 met primary | ||||||
| Phase 1 | NCT06248801 | Sep → Oct 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04087525 | Oct → Nov 2018 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01582308 | Jun → Dec 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT01537120 | Dec 2011 → Oct 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT00567047 | Jul 2007 → Jan 2009 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00419887 | Sep 2006 → ? | — | Novartis | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04410341 | May 2020 → Dec 2024 | major depressive disorder | Sadat City University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00818571 | Dec 2008 → May 2009 | diabetes mellitus, impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00633997 | Feb → Dec 2008 | type 2 diabetes mellitus | Novartis | Terminated | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT04761861 | Feb 2021 → Dec 2025 | hyperlipidemia, schizophrenia | Sadat City University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02803892 | May 2016 → Dec 2018 | type 1 diabetes mellitus | Piemonti Lorenzo | Completed | Missed primary |
| Phase 2 | NCT01452113 | Oct 2010 → Jan 2013 | diabetes mellitus | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT01346254 | Dec 2009 → Nov 2011 | glucose intolerance | Marcus Saemann | Completed | No outcome recorded |
| Phase 2 | NCT00238498 | Jul 2004 → Jun 2005 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00099957 | Sep 2003 → Jun 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00860288 | Feb 2009 → Mar 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT00821977 | Nov 2008 → Oct 2010 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 371 trials · 18 met primary · 5 missed | ||||||
| Phase 3 | NCT04841096 | Mar 2023 → Mar 2024 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT03925701 | Apr 2019 → Dec 2028 expected | — | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT01871558 | Jun 2013 → Feb 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT01811485 | May 2013 → Feb 2014 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01582230 | Apr 2012 → May 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01497522 | Dec 2011 → Feb 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01357252 | Apr 2011 → Jan 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01257451 | Dec 2010 → Mar 2012 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01262586 | Nov 2010 → Mar 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01233622 | Oct 2010 → Nov 2011 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 3 | NCT01822548 | Oct 2010 → Dec 2014 | type 2 diabetes mellitus | Azienda Ospedaliero-Universitaria di Parma | Completed | Met primary |
| Phase 3 | NCT01224366 | Sep 2010 → Oct 2011 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01159249 | Jun 2010 → Jan 2012 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01122641 | May 2010 → Aug 2014 | vascular disorder | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
| Phase 3 | NCT01000688 | Jan → Aug 2010 | type 2 diabetes mellitus | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00822211 | Dec 2008 → Dec 2009 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00770081 | Sep 2008 → Apr 2011 | impaired renal function disease, type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00765830 | Sep 2008 → Apr 2011 | chronic kidney disease, type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00728351 | Jun 2008 → Feb 2010 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00651105 | Feb 2008 → May 2009 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 3 | NCT00616811 | Jan 2008 → Oct 2010 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00494884 | Jun 2007 → Jul 2008 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00468039 | Mar 2007 → Jun 2008 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00396071 | Oct 2006 → Nov 2007 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00396357 | Oct 2006 → Jun 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00396227 | Oct 2006 → Oct 2007 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00389415 | Oct 2006 → ? | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00382096 | Sep 2006 → Jun 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00383578 | Sep 2006 → May 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00390520 | Sep 2006 → Sep 2007 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 3 | NCT00368134 | Aug 2006 → ? | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00351832 | Jun 2006 → ? | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00351884 | May 2006 → Nov 2007 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00325429 | Apr 2006 → ? | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00325117 | Apr 2006 → ? | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00300287 | Feb 2006 → Jun 2007 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00380445 | Jan 2006 → Apr 2007 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00380380 | Jan → Nov 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00260156 | Nov 2005 → Dec 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00237237 | Oct 2005 → Feb 2007 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 3 | NCT00237250 | Oct 2005 → Jul 2006 | prediabetes syndrome | Novartis | Completed | Met primary |
| Phase 3 | NCT00120536 | Jun 2005 → Jul 2006 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 3 | NCT00952991 | May 2005 → Feb 2006 | type 2 diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00351507 | May 2005 → Feb 2006 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00312130 | Apr 2005 → Nov 2006 | prediabetes syndrome | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00110240 | Apr 2005 → Oct 2006 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00646542 | Mar 2005 → Oct 2010 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00106340 | Mar 2005 → May 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00351546 | Feb → Nov 2005 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00138606 | Jan 2005 → Jan 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00102388 | Jan 2005 → Mar 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00138567 | Jan 2005 → Aug 2006 | type 2 diabetes mellitus | Novartis | Completed | Missed primary |
| Phase 3 | NCT00101803 | Jan 2005 → Jan 2006 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00102466 | Jan 2005 → Jan 2009 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00138580 | Nov 2004 → Apr 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00138554 | Nov 2004 → Jul 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00138619 | Nov 2004 → Apr 2007 | type 2 diabetes mellitus | Novartis | Completed | Missed primary |
| Phase 3 | NCT00138515 | Nov 2004 → May 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00230464 | Nov 2004 → Sep 2005 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 3 | NCT00138541 | Oct 2004 → Apr 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00101712 | Oct 2004 → May 2006 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00138593 | Jul 2004 → Jul 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00351585 | Jul 2004 → Sep 2005 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 3 | NCT00099931 | May 2004 → Jun 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00099918 | May 2004 → Sep 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00099853 | May 2004 → Jan 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00099944 | May 2004 → Oct 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099892 | May 2004 → Sep 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099905 | Apr 2004 → Oct 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00101673 | Mar 2004 → Jun 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099866 | Jan 2004 → Aug 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 451 trials · 8 met primary · 3 missed | ||||||
| Phase 4 | NCT06851962 | May 2025 → Jun 2026 | type 2 diabetes mellitus | Fundación para la Investigación del Hospital Clínico de Valencia | Completed | No outcome recorded |
| Phase 4 | NCT07077525 | Jun 2023 → Aug 2024 | type 2 diabetes mellitus | Al-Azhar University | Completed | No outcome recorded |
| Phase 4 | NCT05359432 | Jul 2020 → Aug 2021 | type 2 diabetes mellitus | Getz Pharma | Completed | No outcome recorded |
| Phase 4 | NCT04916093 | Dec 2019 → Jun 2020 | type 2 diabetes mellitus | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT04485845 | Nov 2019 → Aug 2020 | impaired renal function disease, metabolic syndrome X, type 2 diabetes mellitus | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03958591 | May 2019 → Jan 2025 | type 2 diabetes mellitus | Yanbing Li | Completed | No outcome recorded |
| Phase 4 | NCT03693560 | Oct 2018 → Sep 2019 | coronary artery disorder, type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| Phase 4 | NCT04654676 | Sep 2018 → Aug 2019 | type 2 diabetes mellitus | University Malaysia Sarawak | Completed | No outcome recorded |
| Phase 4 | NCT03563794 | Jun 2018 → Jun 2019 | type 2 diabetes mellitus | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 4 | NCT03804411 | Aug 2017 → Mar 2020 | type 2 diabetes mellitus | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Unknown | No outcome recorded |
| Phase 4 | NCT04237493 | Feb → Jul 2017 | type 2 diabetes mellitus | University of Jordan | Completed | No outcome recorded |
| Phase 4 | NCT03253562 | Feb → Aug 2017 | — | MTI University | Completed | No outcome recorded |
| Phase 4 | NCT03983551 | Mar 2016 → Feb 2018 | proteinuria, type 2 diabetes mellitus | Changhua Christian Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02312427 | Jan 2015 → Mar 2016 | congestive heart failure, diabetes mellitus | Mitsui Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03819127 | Jan 2015 → Sep 2016 | cognitive impairment with or without cerebellar ataxia | University of Catania | Completed | No outcome recorded |
| Phase 4 | NCT02176681 | Jun 2014 → Oct 2017 | — | University Hospital, Strasbourg, France | Completed | Missed primary |
| Phase 4 | NCT02089438 | May 2014 → Jun 2017 | type 2 diabetes mellitus | Lund University | Completed | No outcome recorded |
| Phase 4 | NCT01867502 | Apr 2014 → Aug 2015 | hyperglycemia, hypoglycemia, type 2 diabetes mellitus | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT02853630 | Dec 2013 → Nov 2017 | type 2 diabetes mellitus | India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals | Completed | No outcome recorded |
| Phase 4 | NCT02002221 | Dec 2013 → Feb 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01910441 | Jul 2013 → Sep 2014 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01862263 | May 2013 → Jul 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01827280 | Apr 2013 → Aug 2016 | — | Rio de Janeiro State University | Completed | No outcome recorded |
| Phase 4 | NCT01582243 | Apr 2013 → Sep 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01812122 | Mar 2013 → Aug 2015 | type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01758380 | Jan → Sep 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01679899 | Dec 2012 → Oct 2015 | osteoporosis, type 2 diabetes mellitus | Centro de Diabetes Curitiba Ltda | Completed | Missed primary |
| Phase 4 | NCT01686932 | Nov 2012 → Sep 2014 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01604213 | Sep 2012 → Apr 2016 | coronary artery disorder, type 2 diabetes mellitus | Sheba Medical Center | Completed | Met primary |
| Phase 4 | NCT01649466 | Aug 2012 → Oct 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Mixed |
| Phase 4 | NCT01541956 | Feb 2012 → Dec 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01518101 | Jan → Oct 2012 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01219400 | Jan 2012 → Oct 2013 | diabetes mellitus | Lund University | Completed | No outcome recorded |
| Phase 4 | NCT01565096 | Nov 2011 → Nov 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01398592 | Jun 2011 → Jun 2012 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01472432 | May 2011 → Jan 2016 | chronic ulcer of skin | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT01356381 | Apr 2011 → Aug 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01426737 | Apr 2011 → Jan 2013 | type 2 diabetes mellitus | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT01309698 | Feb → Apr 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01238978 | Oct 2010 → Dec 2011 | type 2 diabetes mellitus | Novartis | Completed | Met primary |
| Phase 4 | NCT01426802 | Oct 2010 → Apr 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01147276 | Sep 2010 → Sep 2011 | diabetes mellitus, hypoglycemia | Lund University | Completed | Missed primary |
| Phase 4 | NCT01404676 | Jun 2010 → May 2012 | type 2 diabetes mellitus | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01193296 | Jun 2010 → Jun 2011 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01339143 | Apr 2010 → Dec 2012 | type 2 diabetes mellitus | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01196546 | Mar 2010 → Oct 2011 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01099137 | Jan 2010 → Dec 2012 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | Met primary |
| Phase 4 | NCT01882907 | Dec 2009 → Mar 2013 | type 2 diabetes mellitus | Pusan National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00975065 | Aug 2009 → Dec 2011 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00894868 | May 2009 → Aug 2012 | congestive heart failure, type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT02142309 | Oct 2005 → Oct 2015 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06951334 | Jun 2025 → Dec 2026 expected | Parkinson disease | First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT06313008 | Aug 2023 → Sep 2024 | coronary artery disorder, type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| — | NCT06068686 | Oct 2022 → Nov 2024 | type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| — | NCT05041673 | Feb → Sep 2021 | NAFLD1, type 2 diabetes mellitus | Alexandria University | Unknown | No outcome recorded |
| — | NCT03500900 | Mar 2016 → Jan 2017 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT02506296 | Oct 2014 → Nov 2015 | type 2 diabetes mellitus | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT01703637 | Oct 2012 → Dec 2016 | type 2 diabetes mellitus | Lin Liao | Unknown | No outcome recorded |
| — | NCT01176760 | Aug 2009 → Oct 2011 | — | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| Comparator or background therapy36 trials | ||||||
| Phase 1 | NCT02749032 Comparator | Nov 2011 → Mar 2014 | type 2 diabetes mellitus | Michael A. Nauck | Completed | No outcome recorded |
| Phase 1 | NCT00572650 Comparator | Oct → Nov 2007 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT04300790 Background | Oct 2020 → Jun 2022 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT00980356 Comparator | Sep 2009 → Aug 2012 | diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT01018602 Comparator | Jan 2008 → Jun 2012 | gestational diabetes | Institute of Diabetes Research, Helmholtz Zentrum München | Unknown | No outcome recorded |
| Phase 2/3 | NCT07811011 Comparator | Sep 2026 → Mar 2027 expected | polycystic ovary syndrome | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06142656 Comparator | Nov 2023 → Dec 2025 overdue | polycystic ovary syndrome | October 6 University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00936234 Comparator | Jul 2009 → Sep 2011 | — | Johann Wolfgang Goethe University Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT06021119 Comparator | Mar → Apr 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT06348706 Comparator | Nov 2022 → Dec 2023 | metabolic dysfunction-associated steatohepatitis, type 1 diabetes mellitus | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05369793 Comparator | Aug 2022 → Oct 2023 | diabetic neuropathy, type 2 diabetes mellitus | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT05102149 Comparator | Sep 2021 → Nov 2023 | type 2 diabetes mellitus | PegBio Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02849899 Comparator | Oct 2018 → Jun 2026 | diabetes mellitus, disease related to solid organ transplantation | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 3 | NCT02343926 Comparator | Dec 2014 → Apr 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01559025 Comparator | Mar 2014 → Mar 2015 | type 1 diabetes mellitus | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT03088670 Comparator | Apr 2013 → Mar 2014 | type 2 diabetes mellitus | SatRx LLC | Completed | No outcome recorded |
| Phase 3 | NCT01242228 Background | Oct 2010 → Jun 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05366868 Comparator | May 2022 → Aug 2026 overdue | type 2 diabetes mellitus | National Center for Global Health and Medicine, Japan | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03014479 Comparator | Feb → Oct 2017 | type 2 diabetes mellitus | Takeda | Completed | Missed primary |
| Phase 4 | NCT02999841 Comparator | Mar 2016 → Dec 2017 | obesity disorder, type 2 diabetes mellitus | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02475070 Comparator | Jan 2016 → Jun 2017 | type 2 diabetes mellitus | Lund University | Completed | No outcome recorded |
| Phase 4 | NCT02832999 Comparator | Jan → Sep 2016 | type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT03178591 Comparator | Oct 2014 → Jul 2018 | coronary artery disorder, type 2 diabetes mellitus | Chiang Mai University | Completed | No outcome recorded |
| Phase 4 | NCT02007278 Comparator | Jan 2014 → Feb 2016 | hypoglycemia, type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02145611 Comparator | Jul 2013 → May 2016 | hypertensive disorder, type 2 diabetes mellitus | Dr. José Fernando Vilela-Martin MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT01766778 Comparator | May 2013 → Oct 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01528254 Comparator | Mar 2012 → Apr 2019 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01757587 Comparator | Dec 2011 → Mar 2015 | type 2 diabetes mellitus | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | Completed | No outcome recorded |
| — | NCT06889909 Comparator | Dec 2024 → Jun 2025 overdue | type 2 diabetes mellitus | Lahore General Hospital | Active not recruiting | No outcome recorded |
| — | NCT06913101 Comparator | Nov 2024 → May 2025 overdue | type 2 diabetes mellitus | PNS Hafeez - Naval Hospital | Active not recruiting | No outcome recorded |
| — | NCT02244164 Comparator | Oct 2014 → Feb 2023 | type 2 diabetes mellitus | Erasme University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01083992 Background | Apr 2012 → Jan 2013 | NAFLD1 | Ziv Hospital | Unknown | No outcome recorded |
| — | NCT01176708 Background | Jul 2009 → Aug 2012 | — | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT01922492 Comparator | May 2008 → Dec 2017 | benign neoplasm of pancreas | Seoul National University Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-18 | Novartis Pharmaceuticals | Results Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin novartis.com ↗
Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-18 | Novartis Pharmaceuticals | Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin novartis.com ↗ |
| 2014-08-28 | Hanmi Pharmaceutical Company Limited | Hanmi-Novartis, ‘Galvus’ countrywide symposium hanmipharm.com ↗ |
| 2014-07-09 | Hanmi Pharmaceutical Company Limited | Hanmi-Novartis, co-marketing 'Galvus', treatment for diabetes hanmipharm.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 187 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vildagliptin | “AIM: To investigate the efficacy and safety of vildagliptin as an add-on therapy on glucose excursions of Iftar Ramadan meals among adolescents and young adults with type 1...” PMID 38057844 ↗ Dec 2023178“DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured.” NCT02312427 ↗ “Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose.” NCT01922492 ↗ “50 g-oral glucose tolerance test (OGTT)±vildagliptin, a DPP4 inhibitor (DPP4i) and isoglycaemic i.v. glucose infusion (IIGI), copying the OGTT without DPP4i.” PMID 23704713 ↗ Jul 2013 “Subsequently, patients are assigned to receive either the DPP-4 inhibitor Vildagliptin 50 mg twice daily or the sulfonylurea Glimepiride 2 mg twice daily.” NCT03983551 ↗ “Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes” NCT05041673 ↗ “Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors” NCT06449235 ↗ “Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.” NCT05369793 ↗ “Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin” NCT03014479 ↗ “Vildagliptin, an oral antihyperglycemic agent that competitively inhibits DPP-4.” NCT06348706 ↗ “Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily” NCT01811485 ↗ |
| Known as | - vildagliptine (Galvus) | “- vildagliptine (Galvus®)” NCT02244164 ↗ |
| Known as | Equa | ChEMBL registry synonym — accepted as the source's own label CHEMBL142703 ↗ |
| Known as | Galvus | “Patients who exhibit impaired glucose tolerance (IGT) after kidney transplantation are randomized to either receive vildagliptin (Galvus), pioglitazone(Actos) or placebo for...” NCT01346254 ↗8“Patients were randomized to vildagliptin (Galvus) 100 mg given in the morning (AM), vildagliptin 100 mg given in the evening (PM), or placebo.” PMID 19221978 ↗ Feb 2009 “Evaluation of Galvus (Vildagliptin) Efficacy Versus Placebo” NCT01757587 ↗ “Vildagliptin (Galvus)” NCT07811011 ↗ “Galvus (vildagliptin)” NCT01339143 ↗ “Vildagliptin (Galvus)” NCT02176681 ↗ “Vildagliptin (Galvus)” NCT06851962 ↗ “Galvus (vitagliptin)” NCT01083992 ↗ “Galvus” NCT01176708 ↗ |
| Known as | Jalra | ChEMBL registry synonym — accepted as the source's own label CHEMBL142703 ↗ |
| Known as | LAF237 | “This study will evaluate the pharmacokinetics of vildagliptin (LAF237) and its metabolites in patients with mild renal impairment compared to their sex, age and weigh based...” NCT00572650 ↗5“Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks.” NCT02002221 ↗ “Vildagliptin (LAF237)” NCT00419887 ↗ |
| Known as | NVP-LAF 237 | ChEMBL registry synonym — accepted as the source's own label CHEMBL142703 ↗ |
| Known as | Vilda | “The overarching hypothesis of this study is that vildagliptin (vilda) as add on therapy to metformin (met) in Egyptian type 2 diabetic obese patient will produce an equal, if...” NCT07077525 ↗ |
| Known as | Vildagliptin (galvus) | “Vildagliptin (galvus)” NCT01827280 ↗ |
| Known as | Vildagliptin (Galvus) LAF237 | “Vildagliptin (Galvus) LAF237” NCT01686932 ↗ |
| Known as | Vildagliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL142703 ↗ |
| Known as | vildagliptine | “- vildagliptine (Galvus®)” NCT02244164 ↗ |
| Known as | vitagliptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01083992 ↗ |
| Known as | Xiliarx | ChEMBL registry synonym — accepted as the source's own label CHEMBL142703 ↗ |
| Action | Inhibit | “the dipeptidyl peptidase-4 inhibitor vildagliptin” PMID 17300592 ↗ Mar 2007 |
| Modality | Other / unclassified | “Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves pancreatic islet function by enhancing both α- and β-cell responsiveness to increased blood glucose.” PMID 20925938 ↗ Oct 2010 |
| Route | Oral | “patients will ingest 100 mg of LAF237 or placebo with 200 ml of water” NCT00230464 ↗ |
| Target | DPP4 | “the dipeptidyl peptidase-4 inhibitor vildagliptin” PMID 17300592 ↗ Mar 2007 |